Monday, December 4, 2023
Medscape, LLC requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated. Others involved in the planning of this activity have no relevant financial relationships.
Associate Professor of Medicine
Harvard Medical School
Associate Director, Susan F. Smith Center for Women's Cancers
Director, Clinical Trials, Breast Oncology
Dana-Farber Cancer Institute
Boston, Massachusetts, United States
Professor of Surgery
Harvard Medical School
Rob and Karen Hale Distinguished Chair in Surgical Oncology
Dana-Farber Brigham Cancer Center
Boston, Massachusetts, United States
Head, International Breast Cancer Center (IBCC)
Medica Scientia Innovation Research (MedSIR)
Barcelona, Spain
Professor of Medicine
Director, Breast Oncology and Clinical Trials Education
University of California San Francisco
Comprehensive Cancer Center
San Francisco, California, United States
This activity is intended for hematology and oncology specialists, surgeons, obstetricians, and gynecologists.
The goal of this activity is for the learner to be better able to approach challenging cases in the clinic when making decisions regarding adjuvant therapy for patients with HR-positive, HER2-negative early breast cancer.
Upon completion of this activity, participants will:
Medscape, LLC requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated. Others involved in the planning of this activity have no relevant financial relationships.
Associate Professor of Medicine
Harvard Medical School
Associate Director, Susan F. Smith Center for Women's Cancers
Director, Clinical Trials, Breast Oncology
Dana-Farber Cancer Institute
Boston, Massachusetts, United States
Professor of Surgery
Harvard Medical School
Rob and Karen Hale Distinguished Chair in Surgical Oncology
Dana-Farber Brigham Cancer Center
Boston, Massachusetts, United States
Head, International Breast Cancer Center (IBCC)
Medica Scientia Innovation Research (MedSIR)
Barcelona, Spain
Professor of Medicine
Director, Breast Oncology and Clinical Trials Education
University of California San Francisco
Comprehensive Cancer Center
San Francisco, California, United States
Medscape, LLC designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.50 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregate participant data will be shared with commercial supporters of this activity.
For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]
There are no fees for participating in or receiving credit for this online educational activity. For information on applicability
and acceptance of continuing education credit for this activity, please consult your professional licensing board.
This activity is designed to be completed within the time designated on the title page; physicians should claim only those
credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the
activity online during the valid credit period that is noted on the title page. To receive
AMA PRA Category 1 Credit™, you must receive a minimum score of 75% on the post-test.
Follow these steps to earn CME/CE credit*:
You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it.
Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print
out the tally as well as the certificates from the CME/CE Tracker.
*The credit that you receive is based on your user profile.
CME / ABIM MOC Released: 11/28/2022
Valid for credit through: 11/28/2023, 11:59 PM EST
processing....
Download the pdf.
| « Return to: Assessing Risk in Hormone Receptor-Positive/HER2-Negative Early Breast Cancer: How to Approach Challenging Cases in the Clinic |
